Novo Nordisk increased its annual profit guidance after first-quarter sales rose 32% to 96.8 billion Danish kroner, driven by strong demand for its weight-loss drugs. Operating profit jumped 65% to 59.6 billion kroner, surpassing analyst estimates. Sales of the injectable Wegovy rose 12%, while Ozempic sales fell 8%, and the new oral Wegovy pill launched with 1.3 million prescriptions in the U.S. The company now expects adjusted sales and operating profit to decline by 4% to 12% in 2026, reflecting cautious outlook despite strong early sales momentum.
The European Commission has approved Novo Nordisk's Wegovy pill, the first oral GLP-1 receptor agonist for weight management across the EU. This approval covers adults with obesity or overweight with related health issues and follows positive clinica...
The global blood glucose monitoring system market, valued at $16.8 billion in 2025, is projected to grow to $39.4 billion by 2035 at an 8.9% CAGR. Growth is fueled by rising diabetes prevalence, advancements in AI-enabled monitoring devices, and incr...
